125 related articles for article (PubMed ID: 38622090)
1. Retinoprotective Effect of SkQ1, Visomitin Eye Drops, Is Associated with Suppression of P38 MAPK and ERK1/2 Signaling Pathways Activity.
Muraleva NA; Zhdankina AA; Fursova AZ; Kolosova NG
Biochemistry (Mosc); 2024 Feb; 89(2):201-211. PubMed ID: 38622090
[TBL] [Abstract][Full Text] [Related]
2. Preventive and therapeutic effects of SkQ1-containing Visomitin eye drops against light-induced retinal degeneration.
Novikova YP; Gancharova OS; Eichler OV; Philippov PP; Grigoryan EN
Biochemistry (Mosc); 2014 Oct; 79(10):1101-10. PubMed ID: 25519068
[TBL] [Abstract][Full Text] [Related]
3. The mitochondria-targeted antioxidant SkQ1 restores αB-crystallin expression and protects against AMD-like retinopathy in OXYS rats.
Muraleva NA; Kozhevnikova OS; Zhdankina AA; Stefanova NA; Karamysheva TV; Fursova AZ; Kolosova NG
Cell Cycle; 2014; 13(22):3499-505. PubMed ID: 25483086
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic action of the mitochondria-targeted antioxidant SkQ1 on retinopathy in OXYS rats linked with improvement of VEGF and PEDF gene expression.
Markovets AM; Fursova AZ; Kolosova NG
PLoS One; 2011; 6(7):e21682. PubMed ID: 21750722
[TBL] [Abstract][Full Text] [Related]
5. MEK1/2-ERK Pathway Alterations as a Therapeutic Target in Sporadic Alzheimer's Disease: A Study in Senescence-Accelerated OXYS Rats.
Muraleva NA; Kolosova NG; Stefanova NA
Antioxidants (Basel); 2021 Jun; 10(7):. PubMed ID: 34208998
[TBL] [Abstract][Full Text] [Related]
6. SkQ1 Suppresses the p38 MAPK Signaling Pathway Involved in Alzheimer's Disease-Like Pathology in OXYS Rats.
Muraleva NA; Stefanova NA; Kolosova NG
Antioxidants (Basel); 2020 Jul; 9(8):. PubMed ID: 32731533
[TBL] [Abstract][Full Text] [Related]
7. P38 MAPK Signaling in the Retina: Effects of Aging and Age-Related Macular Degeneration.
Muraleva NA; Kolosova NG
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511345
[TBL] [Abstract][Full Text] [Related]
8. Results of a Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study of the Efficacy and Safety of Visomitin Eye Drops in Patients with Dry Eye Syndrome.
Brzheskiy VV; Efimova EL; Vorontsova TN; Alekseev VN; Gusarevich OG; Shaidurova KN; Ryabtseva AA; Andryukhina OM; Kamenskikh TG; Sumarokova ES; Miljudin ES; Egorov EA; Lebedev OI; Surov AV; Korol AR; Nasinnyk IO; Bezditko PA; Muzhychuk OP; Vygodin VA; Yani EV; Savchenko AY; Karger EM; Fedorkin ON; Mironov AN; Ostapenko V; Popeko NA; Skulachev VP; Skulachev MV
Adv Ther; 2015 Dec; 32(12):1263-79. PubMed ID: 26660938
[TBL] [Abstract][Full Text] [Related]
9. Alzheimer's disease-like pathology in senescence-accelerated OXYS rats can be partially retarded with mitochondria-targeted antioxidant SkQ1.
Stefanova NA; Muraleva NA; Skulachev VP; Kolosova NG
J Alzheimers Dis; 2014; 38(3):681-94. PubMed ID: 24047616
[TBL] [Abstract][Full Text] [Related]
10. Behavioral effects induced by mitochondria-targeted antioxidant SkQ1 in Wistar and senescence-accelerated OXYS rats.
Stefanova NA; Fursova AZh; Kolosova NG
J Alzheimers Dis; 2010; 21(2):479-91. PubMed ID: 20555140
[TBL] [Abstract][Full Text] [Related]
11. Autophagy as a Target for the Retinoprotective Effects of the Mitochondria-Targeted Antioxidant SkQ1.
Telegina DV; Kozhevnikova OS; Fursova AZ; Kolosova NG
Biochemistry (Mosc); 2020 Dec; 85(12):1640-1649. PubMed ID: 33705301
[TBL] [Abstract][Full Text] [Related]
12. Ameliorative effects of SkQ1 eye drops on cataractogenesis in senescence-accelerated OXYS rats.
Rumyantseva YV; Ryabchikova EI; Fursova AZ; Kolosova NG
Graefes Arch Clin Exp Ophthalmol; 2015 Feb; 253(2):237-48. PubMed ID: 25267419
[TBL] [Abstract][Full Text] [Related]
13. Alteration of the MEK1/2-ERK1/2 Signaling Pathway in the Retina Associated with Age and Development of AMD-Like Retinopathy.
Muraleva NA; Kolosova NG
Biochemistry (Mosc); 2023 Feb; 88(2):179-188. PubMed ID: 37072329
[TBL] [Abstract][Full Text] [Related]
14. The glutamate/GABA system in the retina of male rats: effects of aging, neurodegeneration, and supplementation with melatonin and antioxidant SkQ1.
Telegina DV; Antonenko AK; Fursova AZ; Kolosova NG
Biogerontology; 2022 Oct; 23(5):571-585. PubMed ID: 35969289
[TBL] [Abstract][Full Text] [Related]
15. SkQ1 as a Tool for Controlling Accelerated Senescence Program: Experiments with OXYS Rats.
Kolosova NG; Kozhevnikova OS; Muraleva NA; Rudnitskaya EA; Rumyantseva YV; Stefanova NA; Telegina DV; Tyumentsev MA; Fursova AZ
Biochemistry (Mosc); 2022 Dec; 87(12):1552-1562. PubMed ID: 36717446
[TBL] [Abstract][Full Text] [Related]
16. Influence of Antioxidant SkQ1 on Accumulation of Mitochondrial DNA Deletions in the Hippocampus of Senescence-Accelerated OXYS Rats.
Loshchenova PS; Sinitsyna OI; Fedoseeva LA; Stefanova NA; Kolosova NG
Biochemistry (Mosc); 2015 May; 80(5):596-603. PubMed ID: 26071779
[TBL] [Abstract][Full Text] [Related]
17. The Mitochondria-Targeted Antioxidant SkQ1 Downregulates Aryl Hydrocarbon Receptor-Dependent Genes in the Retina of OXYS Rats with AMD-Like Retinopathy.
Perepechaeva ML; Grishanova AY; Rudnitskaya EA; Kolosova NG
J Ophthalmol; 2014; 2014():530943. PubMed ID: 25132985
[TBL] [Abstract][Full Text] [Related]
18. Suppression of Alzheimer's Disease-Like Pathology Progression by Mitochondria-Targeted Antioxidant SkQ1: A Transcriptome Profiling Study.
Stefanova NA; Ershov NI; Kolosova NG
Oxid Med Cell Longev; 2019; 2019():3984906. PubMed ID: 31396299
[TBL] [Abstract][Full Text] [Related]
19. p38 MAPK-dependent alphaB-crystallin phosphorylation in Alzheimer's disease-like pathology in OXYS rats.
Muraleva NA; Kolosova NG; Stefanova NA
Exp Gerontol; 2019 May; 119():45-52. PubMed ID: 30664924
[TBL] [Abstract][Full Text] [Related]
20. Antioxidant SkQ1 Alleviates Signs of Alzheimer's Disease-like Pathology in Old OXYS Rats by Reversing Mitochondrial Deterioration.
Kolosova NG; Tyumentsev MA; Muraleva NA; Kiseleva E; Vitovtov AO; Stefanova NA
Curr Alzheimer Res; 2017; 14(12):1283-1292. PubMed ID: 28637402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
